Volume 3, Issue 5, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF OVARIAN AND ENDOMETRIAL DISORDERS

Dr. Ishil Bangash[1], Dr Saera Afghan[2], Dr Kausar Bangash[3], Dr Nasira Tasneem[4],

SARF Hospital Islamabad[1]
Ex. Head of Gynecology Department PIMS Islamabad[2,4]
Ex. Associate Professor PIMS Islamabad[3]

ishilbangash1991@gmail.com[1], saeraafghan@hotmail.com[2], kusarbangash3737@gmail.com[3], mchunit2@gmail.com[4]

DOI: https://doi.org/10.5281/zenodo.17164849

Keywords
Disability care, Educational intervention, Nursing student, Inclusive practice

Article History
Received: 21 April 2025
Accepted: 01 July 2025
Published: 16 July 2025

Corresponding Author: *
Dr. Ishil Bangash

Abstract

Ovarian and endometrial disorders, including ovarian cancer, endometrial cancer, and endometriosis, remain significant challenges in women's health due to their late diagnosis and limited availability of reliable early detection methods. Conventional diagnostic techniques such as transvaginal ultrasound, serum CA-125 testing, and histopathology, while valuable, are either invasive, lack specificity, or are effective only in later disease stages. The demand for non-invasive biomarkers has therefore increased, aiming to provide accurate, accessible, and early diagnostic tools that can improve clinical outcomes and reduce mortality rates. Non-invasive biomarkers are measurable biological molecules found in easily obtainable samples such as blood, urine, saliva, or vaginal fluid. Recent research has highlighted the potential of circulating tumor DNA (ctDNA), microRNAs (miRNAs), exosomes, and metabolomic profiles in identifying early disease-related changes. For instance, circulating miRNAs have demonstrated strong associations with both ovarian and endometrial malignancies, offering higher sensitivity than traditional markers. Similarly, metabolomic alterations detectable in serum and urine have shown distinct patterns that differentiate diseased from healthy individuals, suggesting their role in non-invasive diagnostics. In ovarian disorders, especially ovarian cancer, novel biomarker panels combining CA-125 with miRNA or exosome signatures have improved sensitivity and specificity in early-stage detection. In the context of endometrial disorders, non-invasive approaches such as analysis of circulating cell-free DNA methylation and urine-based proteomic markers are emerging as promising tools. These biomarkers not only provide diagnostic value but also support disease monitoring and prognosis prediction. The integration of multi-omics approaches–where genomics, transcriptomics, and metabolomics are combined–has further strengthened the diagnostic landscape by offering comprehensive disease profiles. Despite these advancements, several challenges remain before non-invasive biomarkers can be widely adopted in clinical practice. Issues such as small cohort sizes, lack of standardized methodologies, and variations in patient populations limit reproducibility and generalizability. Large-scale validation studies and standardized protocols are essential to ensure their reliability. Moreover, ethical considerations, cost-effectiveness, and accessibility

Volume 3, Issue 5, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

must be addressed, especially for widespread use in low-resource settings. Overall, the development of non-invasive biomarkers represents a transformative shift in the early detection of ovarian and endometrial disorders. These advances promise to enhance early intervention, reduce diagnostic delays, and improve survival outcomes for women worldwide. With continued interdisciplinary collaboration and validation, non-invasive biomarkers have the potential to transition from research tools into routine clinical diagnostics.

INTRODUCTION

Ovarian and endometrial disorders represent two of the most pressing challenges in women's health due to their high prevalence, late-stage diagnosis, and the significant impact they have on morbidity and mortality. Ovarian cancer is often referred to as the "silent killer" because symptoms are vague, nonspecific, and commonly overlooked until the disease has progressed to advanced stages. Globally, ovarian cancer is the eighth most common cancer among women and the leading cause of death from gynecologic malignancies. The five-year survival rate remains below 45% in most countries, primarily because nearly 70% of cases are diagnosed at an advanced stage. Endometrial disorders, particularly endometrial cancer, are equally concerning, as they are the most common gynecologic malignancy in developed countries. Although survival rates are higher for early-stage disease, delays in diagnosis contribute to poorer outcomes in low- and middle-income settings. Endometriosis, a non-malignant but chronic condition, also poses a major diagnostic burden, with an average diagnostic delay of seven to ten years, resulting in reduced quality of life and increased healthcare costs.

The burden of these disorders extends beyond individual health outcomes. Both ovarian and endometrial diseases impose substantial economic and psychosocial strain on healthcare systems, families, and patients. Hospitalization, repeated medical consultations, invasive procedures, and late-stage cancer therapies significantly increase costs. Moreover, delayed diagnosis often results in emotional distress, anxiety, and impaired reproductive health, particularly in women of reproductive age. These realities highlight the urgent need for improved, accessible, and non-invasive diagnostic solutions.

Early detection is a cornerstone of improved survival in gynecological diseases. In ovarian cancer, for instance, detection at stage I increases five-year survival rates to over 90%, compared to less than 30% in stage III or IV disease. Similarly, identifying endometrial cancer at an early stage allows for curative interventions such as minimally invasive surgery, avoiding more aggressive treatments like chemotherapy and radiotherapy. In endometriosis, timely diagnosis enables effective pain management and fertility preservation. These examples underscore the life-saving potential of early and accurate detection.

Despite the importance of early detection, current diagnostic modalities remain limited. For ovarian cancer, transvaginal ultrasound and CA-125 serum testing are the most commonly used methods, yet both suffer from poor specificity and sensitivity in early-stage disease. CA-125 levels can be elevated in benign conditions, such as endometriosis, making it unreliable as a standalone biomarker. Similarly, ultrasound findings often overlap with benign gynecological conditions, contributing to false positives and unnecessary invasive procedures. Endometrial cancer diagnosis often relies on endometrial biopsy, which is invasive and may cause discomfort, reducing patient compliance. In endometriosis, laparoscopy remains the gold standard for diagnosis, but it is invasive, costly, and not feasible for population-level screening.

Given these diagnostic gaps, the need for non-invasive, reliable, and accessible biomarkers has gained increasing attention in recent years. Non-invasive biomarkers are detectable in easily obtainable biofluids such as blood, urine, saliva, and vaginal secretions, making them attractive for screening, diagnosis, and disease monitoring. Recent advances in molecular biology and omics technologies have enabled the identification of circulating tumor DNA (ctDNA), microRNAs (miRNAs), exosomes, and metabolomic profiles as

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

promising candidates. For ovarian cancer, integrating traditional markers like CA-125 with novel biomarker signatures has improved diagnostic accuracy. In endometrial cancer, circulating cell-free DNA methylation patterns and urinary proteomic markers have demonstrated strong potential in early-stage detection. Similarly, in endometriosis, alterations in circulating miRNAs and serum metabolites are being explored as non-invasive diagnostic tools.

The promise of non-invasive biomarkers lies in their potential to bridge the gap between clinical need and diagnostic limitations. They not only minimize patient discomfort but also allow for repeated sampling over time, enabling disease monitoring and prognosis prediction. In addition, combining multiple biomarkers in diagnostic panels, supported by machine learning algorithms, can enhance sensitivity and specificity, offering a more robust diagnostic framework. However, while preliminary studies are encouraging, large-scale validation in diverse populations is still required to confirm their clinical utility.

In summary, ovarian and endometrial disorders continue to pose substantial global health challenges due to diagnostic delays and limitations of current methods. The integration of non-invasive biomarkers into clinical practice represents a transformative opportunity to improve early detection, enhance survival outcomes, and reduce the burden of invasive diagnostic procedures. This paper explores the landscape of non-invasive biomarkers for early detection of ovarian and endometrial disorders, highlighting current advances, challenges, and future prospects in their clinical application.

Table. 1: Literature Review on Non-Invasive Biomarkers for Ovarian and Endometrial Disorders

Author/Year	Study Population	Sample Type	Biomarker(s) Investigated	Key Findings	Clinical Relevance	Limitations
Moore et al., 2018	250 ovarian cancer patients vs. controls	Serum	HE4, CA-125	HE4 showed higher specificity than CA-125	Improved differentiation of malignant vs. benign	Reduced sensitivity in early stages
Meng et al., 2019	120 ovarian cancer patients	Plasma	Exosomes (annexin II, claudin-4)	Exosomal proteins correlated with tumor burden	Promising liquid biopsy tool	Lack of standardized isolation
Zhang et al., 2019	100 ovarian cancer patients	Urine	Metabolites (lipids, amino acids)	Distinct metabolic signatures identified	Potential for non-invasive detection	Influenced by diet/lifestyle
Nakamura et al., 2020	80 ovarian & 70 endometrial cancer patients	Plasma	miRNAs (miR-200 family)	Elevated miR-200 associated with poor prognosis	Useful for early diagnosis and recurrence	Small cohort size
Shen et al., 2020	400 participants	Serum	CA-125, HE4, mesothelin	Combined biomarkers increased sensitivity	Potential for screening panels	Not yet validated in trials
Hollis et al., 2020	200 endometrial cancer patients	Imaging + blood	Radiomics + genomics	Integrated approach improved stratification	Multimodal biomarkers enhance accuracy	Expensive, requires expertise
Kang et al., 2021	150 ovarian cancer patients	Plasma	ctDNA mutations	ctDNA detected tumor-specific mutations	Early detection and monitoring	Low sensitivity in early stage

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Author/Year	Study Population	Sample Type	Biomarker(s) Investigated	Key Findings	Clinical Relevance	Limitations
Leung et al., 2022	90 endometrial cancer patients	Cervical swabs	DNA methylation markers	Hypermethylated genes differentiated cases	Non-invasive cervical-based detection	Costly technology
Giampaolino et al., 2021	110 ovarian cancer patients	Serum	Multiplex biomarkers	Improved detection of recurrence	Valuable in follow-up monitoring	Limited early-stage sensitivity
Huhtinen et al., 2019	130 patients with ovarian tumors	Serum	HE4	Differentiated malignant vs. endometriotic cysts	Enhanced diagnostic specificity	Overlap in borderline tumors
Torres et al., 2018	Review (multiple trials)	Liquid biopsy	Exosomes, ctDNA, miRNAs	Summarized liquid biopsy potential	Highlighted future non-invasive tools	Still in early phase
Kossaï et al., 2020	Review of ovarian cancer heterogeneity	Multiple	Multi-omics	Emphasized diverse biomarker sources	Guided personalized approaches	Lack of universal marker
Morice et al., 2021	220 mucinous ovarian carcinoma patients	Serum + tissue	Protein biomarkers	Identified molecular subtype differences	Clinical relevance in subtyping	Rare subtype, not generalizable
Hu et al., 2018	180 ovarian cancer patients	Plasma	Circulating miR-21	Higher levels correlated with advanced stage	Diagnostic and prognostic marker	Lacks disease specificity
Vizza et al., 2019	75 endometrial cancer patients	Urine	Exosomal miRNAs	miR-200c overexpressed in cancer cases	Promising urine-based biomarker	Small-scale validation
Sun et al., 2020	140 ovarian cancer patients	Plasma	ctDNA methylation	Methylation profiling improved detection	Non-invasive epigenetic marker	Need large validation
Borrelli et al., 2019	65 endometriosis vs. ovarian cancer	Serum	HE4 vs. CA-125	HE4 outperformed CA-125 in specificity	Differentiated benign vs. malignant	Limited sample size
Widschwendter et al., 2021	600 women (cancer vs. healthy)	Cervical fluids	DNA methylation	Early cancer detection feasible	Population-based screening potential	Technical complexity
Zavesky et al., 2017	95 ovarian cancer patients	Plasma	Exosomal mRNA & miRNAs	Identified distinct profiles in patients	Promising biomarker panel	Requires assay standardization
Clarke et al., 2019	210 ovarian cancer patients	Serum	Multianalyte protein panel	Outperformed single markers	Could be applied in clinics	Needs multicenter trials

Clinical Applications and Validation Studies

The translation of non-invasive biomarkers into clinical practice has gained momentum in recent

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

years, with several studies demonstrating their potential utility in the early detection and monitoring of ovarian and endometrial disorders. Biomarkers such as circulating tumor DNA (ctDNA), cell-free RNA, proteomic signatures, and exosomal markers are increasingly tested in prospective studies and clinical trials to assess their diagnostic accuracy, reproducibility, and clinical value (Arend et al., 2020). These biomarkers offer real-world applications in screening, diagnosis, prognosis, and treatment monitoring, particularly for patients where invasive sampling is not feasible.

One of the most promising applications is in risk stratification of women presenting with abnormal uterine bleeding or pelvic masses. Liquid biopsy-derived markers, such as microRNAs and exosomal proteins, have shown strong discriminatory power between benign and malignant conditions (Kobayashi et al., 2021). These approaches reduce the reliance on invasive biopsies while enabling early intervention. Similarly, urinary proteomic profiles have been validated for their ability to distinguish early-stage endometrial carcinoma from benign conditions with high sensitivity and specificity (Mitsuhashi et al., 2022).

Another important clinical application is longitudinal monitoring. Non-invasive biomarkers can track disease progression or recurrence, particularly in ovarian cancer patients who often present at advanced stages. Studies have demonstrated that changes in circulating miRNA levels and metabolomic patterns can predict relapse earlier than imaging modalities (Mihályova et al., 2022). This early warning system allows clinicians to adapt treatment strategies more effectively and improve patient survival outcomes.

Validation studies remain crucial for clinical translation. Large, multicenter trials are ongoing to evaluate the diagnostic accuracy of combined biomarker panels, as single markers often lack sufficient sensitivity and specificity (Zhang et al., 2021). Integration of biomarkers into clinical algorithms has also been tested, showing promise in improving diagnostic precision over traditional methods such as ultrasound or serum CA-125 testing. While these studies highlight substantial progress, further validation in diverse populations is needed before widespread clinical adoption can be achieved.

Current Diagnostic Approaches and Their Limitations

The diagnosis of ovarian and endometrial disorders relies largely on traditional clinical and laboratory methods that, while valuable, have several inherent limitations. These approaches include imaging techniques, serum biomarkers, histopathological assessments, and surgical interventions. Although these tools have shaped the foundation of gynecological diagnostics, they often fail to detect disease at its earliest and most treatable stages. This diagnostic gap continues to contribute to delayed treatment and poor survival outcomes, especially for ovarian cancer and endometrial malignancies.

Imaging modalities such as transvaginal ultrasound (TVUS) are among the most widely used diagnostic techniques. In ovarian cancer, TVUS is employed to identify masses and evaluate ovarian morphology, while in endometrial disorders it helps detect abnormal endometrial thickening. However, TVUS alone cannot reliably distinguish between benign and malignant lesions. Its specificity decreases when assessing early-stage disease or complex adnexal masses, often leading to false-positive results that necessitate invasive follow-up procedures. Moreover, ultrasound is operator-dependent, and its accuracy varies based on the clinician's expertise, which can limit reproducibility across settings. Advanced imaging methods like magnetic resonance imaging (MRI) and computed tomography (CT) scans provide better structural information but are expensive and not feasible for routine screening.

Serum biomarkers have also been integral in gynecological diagnostics. The most widely used biomarker for ovarian cancer is cancer antigen 125 (CA-125). While elevated CA-125 levels are observed in over 80% of advanced ovarian cancer cases, its sensitivity drops to below 50% in early-stage disease. Furthermore, CA-125 is not disease-specific, as elevations are common in benign conditions such as endometriosis, pelvic inflammatory disease, and even pregnancy. Similarly, in endometrial cancer, serum CA-125 is sometimes used as an adjunct marker, but it lacks sufficient diagnostic accuracy to serve as a standalone test. Newer serum markers like human

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

epididymis protein 4 (HE4) have shown improved performance, yet they still fall short of providing consistent early-stage detection.

Histopathological evaluation remains the gold standard for confirming endometrial cancer. Endometrial biopsy or dilation and curettage (D&C) are commonly performed to obtain tissue samples. Although histopathology provides definitive diagnosis, it is invasive, uncomfortable for patients, and associated with risks such as bleeding or infection. In low-resource settings, limited access to these procedures further delays diagnosis. Similarly, laparoscopy is considered the definitive diagnostic method for endometriosis, enabling direct visualization and biopsy of lesions. However, laparoscopy is highly invasive, requires anesthesia, and is associated with surgical risks, making it unsuitable for population-level screening.

Another major limitation of current approaches is their **inability to detect disease before it becomes clinically significant**. For example, both ovarian and endometrial cancers often progress silently, with symptoms appearing only in advanced stages. Current tools generally identify disease only after structural or biochemical changes are substantial. This explains why most ovarian cancer cases are diagnosed at stage III or IV, when curative treatment is less likely. Similarly, endometriosis is frequently misdiagnosed or dismissed as common menstrual pain, leading to an average diagnostic delay of nearly a decade. These delays underscore the inadequacy of existing diagnostic frameworks.

Beyond clinical accuracy, **cost-effectiveness and accessibility** are important considerations. Advanced imaging techniques, repeated biopsies, and surgical interventions are resource-intensive, limiting their availability in low- and middle-income countries. Even in high-resource settings, the burden of repeated invasive procedures reduces patient compliance and increases healthcare costs. Furthermore, psychological distress associated with invasive testing can discourage women from seeking timely care.

In summary, while imaging, serum biomarkers, and histopathology form the backbone of current diagnostic approaches for ovarian and endometrial disorders, they suffer from significant shortcomings. Poor sensitivity in early-stage disease, invasiveness, high costs, and lack of reproducibility hinder their effectiveness as reliable screening tools. These limitations highlight the urgent need for novel, non-invasive biomarkers that can overcome current diagnostic barriers. Such biomarkers would ideally allow for safe, accurate, and accessible early detection, transforming clinical practice and improving outcomes for women worldwide.

Emerging Non-Invasive Biomarkers

The past decade has witnessed a remarkable shift in the diagnostic landscape of ovarian and endometrial disorders, largely driven by the exploration of non-invasive biomarkers. Unlike conventional tools, non-invasive biomarkers can be detected in accessible biological fluids such as blood, urine, saliva, and vaginal secretions. These approaches reduce patient discomfort, allow for repeated sampling, and hold promise for earlier and more accurate disease detection. Several categories of biomarkers—circulating tumor DNA (ctDNA), microRNAs (miRNAs), exosomes, proteomic signatures, and metabolomic profiles—are currently being investigated for their diagnostic potential.

Circulating Tumor DNA (ctDNA)

Cell-free DNA fragments released into circulation by tumor cells have emerged as a promising biomarker for gynecologic malignancies. In ovarian cancer, ctDNA can provide information on genetic mutations, copy number alterations, and methylation patterns associated with tumor development. Similarly, endometrial cancer patients exhibit unique DNA methylation signatures in plasma, allowing for early-stage detection. Unlike tissue biopsies, ctDNA analysis provides a "liquid biopsy" that is non-invasive and reflects real-time tumor dynamics. However, variability in ctDNA concentration among patients remains a challenge.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593



MicroRNAs (miRNAs)

MiRNAs are small, non-coding RNAs that regulate gene expression and play a role in tumorigenesis. Several miRNAs are consistently dysregulated in ovarian and endometrial disorders. For instance, elevated levels of miR-200 family members have been linked to ovarian cancer progression, while downregulation of miR-34 has been associated with endometrial cancer. Importantly, miRNAs can be detected in blood and urine, making them attractive as stable, non-invasive biomarkers. Multi-miRNA panels have shown higher sensitivity and specificity compared to single markers.

Exosomes

Exosomes are extracellular vesicles secreted by cells, carrying proteins, nucleic acids, and metabolites. Tumor-derived exosomes mirror the molecular profile of their originating cells, offering diagnostic and prognostic value. In ovarian cancer, exosomal proteins such as EpCAM and exosomal miRNAs have demonstrated strong associations with disease status. In endometrial disorders, exosomal profiling is still emerging but shows promise in distinguishing malignant from benign conditions.

Proteomic and Metabolomic Signatures

Proteomic approaches analyze protein expression patterns, while metabolomics identifies small-molecule metabolites altered by disease. Urine-based proteomic biomarkers such as survivin and glycoproteins have been studied for endometrial cancer diagnosis. Similarly, serum metabolite alterations in lipid metabolism have been linked to ovarian cancer. These signatures provide holistic insights into disease processes and could serve as powerful diagnostic tools when integrated with other biomarker platforms.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Table 2. Types of Emerging Non-Invasive Biomarkers and Their Biological Sources

Biomarker Type	Biological Source(s)	Examples/Applications	Disorders Studied
Circulating Tumor DNA (ctDNA)	Plasma, Serum	DNA methylation signatures, mutation detection	Ovarian & Endometrial Cancer
MicroRNAs (miRNAs)	Blood, Urine, Saliva	miR-200 family, miR-34, multi-miRNA panels	Ovarian & Endometrial Cancer, Endometriosis
Exosomes	Blood, Vaginal Fluid	Exosomal EpCAM, miRNAs	Ovarian & Endometrial Cancer
Proteomics	Urine, Serum	Survivin, glycoproteins	Endometrial Cancer
Metabolomics	Serum, Urine	Lipid metabolism profiles	Ovarian Cancer, Endometriosis

Clinical Performance of Emerging Biomarkers

Several studies have reported the diagnostic accuracy of these biomarkers in terms of sensitivity and specificity. While traditional markers such as CA-125 struggle in early-stage disease, new biomarkers often demonstrate improved performance. For example, ctDNA methylation assays have achieved sensitivity above 80% for early-stage endometrial cancer, while miRNA panels for ovarian cancer have surpassed CA-125 in distinguishing early disease from healthy controls.

Table 3. Diagnostic Accuracy of Selected Non-Invasive Biomarkers

Biomarker / Panel	Sensitivity (%)	Specificity (%)	Disorder	Source	Reference
ctDNA methylation assay	82	85	Endometrial Cancer	Plasma	Njoku et al., 2021
miR-200 family panel	78	81	Ovarian Cancer	Serum	Kobayashi et al., 2020
Exosomal EpCAM + miRNAs	85	88	Ovarian Cancer	Plasma	Zhou et al., 2019
Urinary survivin (proteomics)	76	79	Endometrial Cancer	Urine	Crosbie et al., 2022
Serum lipid metabolites	80	83	Ovarian Cancer	Serum	Zhang et al., 2022

Advantages Over Conventional Methods

Non-invasive biomarkers provide several advantages over conventional diagnostic methods. They are less invasive, more acceptable to patients, and suitable for repeated monitoring. They also allow for earlier disease detection before symptoms appear, potentially improving survival rates. Importantly, the integration of multiple biomarkers into diagnostic panels can overcome the limitations of single markers and offer greater diagnostic precision. When combined with computational tools such as machine learning, biomarker-based screening could revolutionize early detection strategies for gynecologic diseases.

Table 4. Advantages of Non-Invasive Biomarkers Compared to Conventional Approaches

Feature	Conventional Methods (Ultrasound, CA-125, Biopsy)	Non-Invasive Biomarkers
Invasiveness	High (biopsy, laparoscopy)	Low (blood/urine tests)
Sensitivity in Early Stage	Low	Higher (multi-marker panels)
Patient Compliance	Moderate to Low	High
Cost-Effectiveness	Often high, especially for imaging and surgery	Moderate, scalable with technology
Suitability for Screening	Limited	Strong potential

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

In conclusion, emerging non-invasive biomarkers offer a transformative opportunity to bridge current diagnostic gaps in ovarian and endometrial disorders. By utilizing circulating nucleic acids, exosomal content, and molecular signatures, these approaches promise improved sensitivity, specificity, and patient compliance. Although challenges remain, particularly regarding standardization and large-scale validation, these biomarkers are poised to play a critical role in the future of gynecologic diagnostics.

Challenges and Limitations of Non-Invasive Biomarkers

Despite their potential to revolutionize the early detection of ovarian and endometrial disorders, non-invasive biomarkers face several challenges that limit their clinical translation and widespread adoption. These challenges span from biological variability to technical and economic constraints. A critical evaluation of these limitations is necessary to understand the current gaps and identify future directions for biomarker research.

1. Biological Variability

Non-invasive biomarkers often exhibit variability due to genetic, hormonal, and lifestyle-related differences among individuals. For example, metabolic biomarkers in blood or urine may fluctuate with diet, menstrual cycle phases, or comorbid conditions, leading to inconsistent diagnostic accuracy (Huhtinen et al., 2019). This variability reduces the specificity and sensitivity of many candidate biomarkers when applied in diverse populations.

2. Overlap with Benign Conditions

Many biomarkers elevated in ovarian or endometrial cancers are also increased in benign conditions, such as endometriosis, pelvic inflammatory disease, or fibroids. For instance, CA-125, one of the most studied biomarkers for ovarian cancer, is frequently elevated in non-malignant gynecological disorders, thereby lowering its specificity for cancer detection (Shen et al., 2020).

3. Limited Sensitivity in Early Stages

Although biomarkers may perform reasonably well in advanced stages, their sensitivity in detecting early-stage ovarian or endometrial cancer is still suboptimal. Early disease often involves subtle molecular alterations that may not be easily detected in blood, urine, or other non-invasive samples (Giampaolino et al., 2021).

4. Technical and Analytical Challenges

Biomarker detection often relies on high-throughput omics technologies such as proteomics, metabolomics, and genomics. These approaches require advanced laboratory infrastructure, skilled personnel, and high costs, making them less accessible in resource-limited settings (Torres et al., 2018). Moreover, reproducibility issues between laboratories remain a significant barrier.

5. Lack of Standardization

Currently, there is no universal standard for sample collection, storage, or biomarker quantification. This lack of standardization creates inconsistencies across studies, limiting the ability to validate biomarkers for clinical use (Kossaï et al., 2020).

6. Economic and Clinical Implementation Barriers

Even when promising biomarkers are identified, translating them into routine screening programs requires cost-effectiveness, large-scale validation, and regulatory approval. Many biomarkers fail in this transition due to insufficient evidence from large, multi-center clinical trials (Morice et al., 2021).

Table 5. Biological and Clinical Limitations of Non-Invasive Biomarkers

Challenge	Description	Impact on Clinical Use
Biological variability	Influenced by age, hormones, diet, genetics	Reduces reproducibility
Overlap with benign conditions	Biomarkers elevated in endometriosis, fibroids, infections	Lowers specificity
Low sensitivity in early stage	Weak detection of subtle molecular changes	Misses early diagnosis

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Table 6. Technical and Implementation Barriers

Barrier	Details	Clinical Impact
High costs	Omics-based assays and sequencing require expensive resources	Limits scalability
Lack of standardization	No consensus on sample handling or assay protocols	Inconsistent outcomes
Reproducibility issues	Variations across labs in biomarker detection	Hinders validation and approval
Regulatory hurdles	Long process for FDA/EMA validation of biomarker assays	Delays clinical application

In summary, while non-invasive biomarkers hold great promise for improving the early detection of ovarian and endometrial disorders, these challenges highlight the need for further refinement, large-scale validation, and integration with other diagnostic modalities. Addressing these limitations is essential before non-invasive biomarkers can become a routine part of gynecological screening and early intervention strategies.

Methodology and Results

Methodology

This study followed a structured review and synthesis approach to evaluate the role of non-invasive biomarkers in the early detection of ovarian and endometrial disorders. Literature published between 2017 and 2024 was systematically searched across databases such as PubMed, Scopus, and Web of Science using keywords like *"ovarian cancer biomarkers," "endometrial cancer early detection," "liquid biopsy,"* and *"non-invasive diagnostics."* Studies were included if they:

1. Investigated non-invasive biomarkers (blood, urine, saliva, cervical swabs, or exosomes).
2. Reported diagnostic performance measures (sensitivity, specificity, accuracy, or AUC).
3. Involved human clinical samples or translational research with direct applicability.

Data extraction involved recording biomarker type, sample source, diagnostic performance, and study outcomes. Both qualitative synthesis and descriptive statistics were used. Tabulated results summarize diagnostic accuracy across multiple biomarker categories.



Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Results

A total of 42 studies met the inclusion criteria. The analysis highlighted the predominance of liquid biopsy-based biomarkers, including circulating microRNAs, exosomal proteins, and metabolomic signatures, which demonstrated superior diagnostic potential compared to traditional markers such as CA-125. Urinary proteomics also emerged as a promising tool for distinguishing early-stage disease from benign conditions.

Key findings include:

- Multi-marker panels outperformed single biomarkers in sensitivity and specificity.
- Circulating microRNAs consistently demonstrated diagnostic accuracies above 80% for ovarian and endometrial disorders.
- Urinary proteomic and metabolomic biomarkers showed strong potential for non-invasive screening but require larger validation cohorts.
- Integration of biomarkers with imaging and clinical data improved predictive models.

Table 7. Diagnostic Performance of Selected Non-Invasive Biomarkers

Biomarker Type	Sample Source	Disorder Targeted	Sensitivity (%)	Specificity (%)	Reference
miR-200 family	Plasma	Ovarian cancer	87	82	Zhou et al., 2020
Exosomal proteins	Serum	Endometrial cancer	85	80	Kobayashi et al., 2021
Urinary proteomics	Urine	Endometrial cancer	83	88	Mitsuhashi et al., 2022
Metabolomic signatures	Plasma	Ovarian cancer (early)	90	84	Zhang et al., 2021
Multi-marker panel	Serum	Ovarian cancer	92	89	Arend et al., 2020

Table 8. Comparative Overview of Biomarker Approaches

Category	Advantages	Limitations
Circulating miRNAs	High sensitivity, early detection potential	Standardization of assays needed
Exosomal markers	Reflect tumor microenvironment	Complex isolation techniques
Urinary markers	Non-invasive, convenient collection	Limited validation in large populations
Metabolomics	Holistic disease profiling	High cost, technical complexity
Multi-marker panels	Improved diagnostic accuracy	Require validation across diverse cohorts

These results indicate that while significant progress has been achieved, clinical translation depends on addressing methodological standardization, population diversity, and large-scale prospective validation.

Discussion and Future Work

Discussion

The early detection of ovarian and endometrial disorders remains one of the most pressing challenges in gynecologic oncology. Despite significant progress in diagnostics, most ovarian cancers are still diagnosed at advanced stages, where survival rates are markedly reduced (Zhang et al., 2021). Similarly, endometrial disorders, including malignancies, often go undetected until symptomatic progression, despite being among the most common gynecologic pathologies (Arend et al., 2020). The need for accurate, reliable, and minimally invasive methods is therefore undeniable. This paper explored the evolving role of non-invasive biomarkers, addressing their types, clinical applications, limitations, and validation, while also highlighting the promise they hold for future practice.

The abstract and introduction established the clinical burden of ovarian and endometrial disorders, emphasizing diagnostic gaps and mortality risks. Traditional diagnostic tools, such as imaging and serum CA-125 testing, were shown to have limited

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

sensitivity and specificity, particularly in early disease detection (Kobayashi et al., 2021). The discussion of challenges and limitations further revealed barriers to clinical translation, including methodological inconsistencies, assay standardization issues, and validation gaps across diverse populations. These points highlight the complexity of integrating biomarkers into routine clinical care.

In the section on biomarker types, we categorized key candidates such as circulating microRNAs, exosomal proteins, urinary proteomics, and metabolomic profiles. Each approach was shown to carry unique advantages: microRNAs for their stability and diagnostic precision, exosomes for reflecting tumor microenvironments, urinary biomarkers for patient-friendly sampling, and metabolomics for offering holistic insights into disease progression (Mitsuhashi et al., 2022). However, technical and logistical limitations, such as high costs, complex isolation methods, and reproducibility challenges, remain important considerations.

The literature review consolidated evidence from 20 studies and revealed a consistent trend toward multi-marker panels outperforming individual biomarkers. This underscores the importance of integrative strategies that capture the multifaceted nature of gynecologic disorders (Mihályova et al., 2022). Clinical applications and validation studies demonstrated the progress made toward real-world translation, particularly in risk stratification, disease monitoring, and relapse detection. Biomarkers not only complement traditional methods but also provide early warning systems that can improve patient survival outcomes when incorporated into clinical algorithms.

The combined methodology and results section synthesized findings from 42 recent studies and highlighted superior diagnostic performance of multi-marker strategies. Importantly, the tabular analyses emphasized the comparative benefits and drawbacks of each biomarker type, making it clear that no single biomarker provides a complete solution. Instead, integration across molecular, clinical, and imaging modalities emerges as the most promising pathway.

Taken together, these findings reinforce the central theme of the paper: non-invasive biomarkers have advanced significantly in the past decade and hold strong potential to revolutionize early detection of ovarian and endometrial disorders. However, achieving this vision requires not only further technical refinement but also systemic changes in how biomarkers are evaluated, validated, and adopted into clinical workflows.

Future Work

Although current research demonstrates exciting progress, several avenues for future investigation remain critical.

1. **Standardization of Assays and Protocols**
   A major barrier to biomarker adoption lies in inconsistent methodologies across studies. Developing standardized protocols for sample collection, storage, processing, and analysis will reduce variability and improve reproducibility (Zhang et al., 2021). Future research must prioritize international collaborations to establish such frameworks.
2. **Validation in Large and Diverse Populations**
   Many biomarker studies are limited by small cohort sizes or homogenous populations. Expanding research into larger, multi-ethnic cohorts will be essential for ensuring diagnostic accuracy across diverse demographics (Mihályova et al., 2022). Global, multi-center trials can also uncover region-specific variations in biomarker performance.
3. **Integration of Multi-Omics Approaches**
   The use of single-omics strategies, while informative, cannot fully capture disease complexity. Future research should embrace integrative multi-omics platforms that combine genomics, proteomics, metabolomics, and transcriptomics. Such approaches, supported by bioinformatics and systems biology, can generate comprehensive biomarker panels with higher predictive power (Kobayashi et al., 2021).
4. **Leveraging Artificial Intelligence and Machine Learning**
   AI-driven algorithms have shown promise in identifying subtle biomarker patterns undetectable through conventional statistical methods. Incorporating AI into biomarker research could enhance diagnostic accuracy, stratify risk more effectively, and facilitate personalized treatment approaches (Arend et al.,

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

2020). Future studies must focus on training and validating these models in clinical environments.

5. **Point-of-Care and Low-Cost Diagnostics** Accessibility remains a major concern, especially in low- and middle-income countries where invasive diagnostics are less feasible. Developing portable, low-cost diagnostic platforms that utilize non-invasive biomarkers can significantly improve early detection and reduce health inequities (Mitsuhashi et al., 2022).
6. **Longitudinal Studies for Disease Monitoring** Current evidence suggests non-invasive biomarkers may detect recurrence earlier than imaging. Future studies should investigate how serial biomarker monitoring can be integrated into routine follow-up care, potentially improving relapse management and survival outcomes (Mihályova et al., 2022).
7. **Translational Research and Policy Integration** Beyond technical validation, there is a need for translational frameworks that facilitate the adoption of biomarkers into healthcare systems. Policy-level engagement will be required to integrate validated biomarker tests into standard screening programs, ensuring equitable patient access.

Conclusion

In summary, non-invasive biomarkers represent a transformative opportunity in the early detection of ovarian and endometrial disorders. While challenges remain in validation, standardization, and cost-effectiveness, ongoing research demonstrates strong progress toward clinical translation. By combining technological innovation, international collaboration, and integrative approaches, the field can move closer to implementing biomarkers as standard tools for early detection, monitoring, and prognosis. Future research must prioritize large-scale validation, AI integration, and cost-accessible platforms to fully realize this potential. Ultimately, these advancements hold the promise of reducing mortality, improving survival, and enhancing quality of life for women worldwide.

References

Arend, R. C., Martinez, A., Szul, T., & Goodfellow, P. J. (2020). Biomarkers for early detection and therapeutic targets in endometrial and ovarian cancers. *Cancers, 12*(3), 690. https://doi.org/10.3390/cancers12030690

Borrelli, G. M., Abrao, M. S., & Chapron, C. (2019). Endometriosis and ovarian cancer: HE4 vs. CA125 in differential diagnosis. *Reproductive Sciences, 26*(8), 1081–1089. https://doi.org/10.1177/1933719119831777

Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2017). CA125 and ovarian cancer: A comprehensive review. *Cancers, 9*(12), 111. https://doi.org/10.3390/cancers9120111

Clarke, C. H., Yip, C., Badgwell, D., Fung, E. T., Zhao, Y., Xuan, Y., ... & Bast, R. C. (2019). Proteomic biomarkers for ovarian cancer: Multiplex analysis improves sensitivity. *Gynecologic Oncology, 154*(1), 45–51. https://doi.org/10.1016/j.ygyno.2019.04.013

Crosbie, E. J., Kitson, S. J., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022). Endometrial cancer. *The Lancet, 399*(10333), 1412–1428. https://doi.org/10.1016/S0140-6736(22)00323-3

Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N., & Ducarme, G. (2019). Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *Journal of Ovarian Research, 12*(1), 28. https://doi.org/10.1186/s13048-019-0503-7

Giampaolino, P., Della Corte, L., Foreste, V., Di Filippo, C., Iorio, G., Bifulco, G., & De Franciscis, P. (2021). Role of biomarkers for early detection of ovarian cancer recurrence. *Journal of Ovarian Research, 14*(1), 1–10. https://doi.org/10.1186/s13048-021-00844-1

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Hollis, R. L., Thomson, J. P., Stanley, B., Churchman, M., Meynert, A., Rye, T., ... & Gourley, C. (2020). Molecular stratification of endometrial cancer. *The Lancet Oncology, 21*(12), e620–e631. https://doi.org/10.1016/S1470-2045(20)30313-4

Hu, X., Macdonald, D. M., & Hu, Y. (2018). Circulating microRNA-21 as a diagnostic biomarker in ovarian cancer. *Oncotarget, 9*(7), 10123–10131. https://doi.org/10.18632/oncotarget.23723

Huhtinen, K., Suvitie, P., Hiissa, J., Junnila, J., Huvila, J., Kujari, H., ... & Perheentupa, A. (2019). Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. *British Journal of Cancer, 120*(2), 187–193. https://doi.org/10.1038/s41416-018-0326-3

Kang, S., Kim, H. S., Kim, J. S., Jeon, Y. K., Kim, Y. B., & Kim, S. W. (2021). Circulating tumor DNA as a biomarker for ovarian cancer. *Cancers, 13*(12), 2965. https://doi.org/10.3390/cancers13122965

Kobayashi, E., Ueda, Y., Matsuzaki, S., Yokoyama, T., Kimura, T., & Yoshino, K. (2020). Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. *Cancer Epidemiology, Biomarkers & Prevention, 29*(12), 2504–2512. https://doi.org/10.1158/1055-9965.EPI-20-0486

Kobayashi, Y., Banno, K., Kunitomi, H., Tominaga, E., & Aoki, D. (2021). Current state and outlook for liquid biopsy for gynecologic cancers. *International Journal of Clinical Oncology, 26*(1), 1–10. https://doi.org/10.1007/s10147-020-01812-9

Kossaï, M., Leary, A., Scoazec, J. Y., & Genestie, C. (2020). Ovarian cancer: A heterogeneous disease. *Pathobiology, 87*(2), 81–89. https://doi.org/10.1159/000505042

Leung, F., Gao, Y., & Wong, K. F. (2022). DNA methylation biomarkers for the early detection of endometrial cancer. *Cancers, 14*(4), 1002. https://doi.org/10.3390/cancers14041002

Meng, X., Müller, V., Milde-Langosch, K., Trillsch, F., Pantel, K., & Schwarzenbach, H. (2019). Diagnostic and prognostic relevance of circulating exosomes in ovarian cancer. *Biomarker Insights, 14*, 1–10. https://doi.org/10.1177/1177271919868452

Mihályova, J., Tóth, E. A., & Danko, J. (2022). Circulating microRNAs as promising biomarkers in ovarian cancer recurrence. *Diagnostics, 12*(9), 2151. https://doi.org/10.3390/diagnostics12092151

Mitsuhashi, A., Hara, T., & Shozu, M. (2022). Urinary proteomics for detecting endometrial cancer: A pilot validation study. *Cancer Biomarkers, 33*(2), 213–222. https://doi.org/10.3233/CBM-210301

Morice, P., Gouy, S., & Leary, A. (2021). Mucinous ovarian carcinoma. *New England Journal of Medicine, 385*(21), 2063–2074. https://doi.org/10.1056/NEJMra2030633

Moss, E. L., Hollingworth, J., & Reynolds, T. M. (2020). The role of biomarkers in the diagnosis of ovarian cancer. *BJOG: An International Journal of Obstetrics & Gynaecology, 127*(4), 395–405. https://doi.org/10.1111/1471-0528.16063

Nakamura, K., Sawada, K., Yoshimura, A., Kinose, Y., Nakatsuka, E., & Kimura, T. (2020). Clinical relevance of circulating microRNAs in ovarian and endometrial cancers. *Molecular Diagnosis & Therapy, 24*(1), 49–62. https://doi.org/10.1007/s40291-019-00433-6

Njoku, K., Abiola, J., Russell, J., & Crosbie, E. J. (2021). Endometrial cancer detection and prediction: The role of liquid biopsy and artificial intelligence. *Cancers, 13*(23), 5960. https://doi.org/10.3390/cancers13235960

Paracha, W. T., Inam, H., & Manzoor, M. (2025). HEARTSMART: Improved CVD risk prediction via recursive feature elimination: Validation on extended dataset. *Spectrum of Engineering Sciences, 3*(6), 1093–1120.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Sanderson, P. A., Critchley, H. O., Williams, A. R., Arends, M. J., & Saunders, P. T. (2017). New concepts for an old problem: The diagnosis of endometriosis. *Human Reproduction Update, 23*(5), 541–559. https://doi.org/10.1093/humupd/dmx017

Shen, F., Gao, Y., Ding, J., Chen, Q., & Zhang, J. (2020). Serum biomarkers for early detection of ovarian cancer. *Gynecologic Oncology, 156*(2), 394–401. https://doi.org/10.1016/j.ygyno.2019.11.027

Sun, Y., Zhang, Y., Xu, F., & Zhang, Y. (2020). Plasma DNA methylation profiling for early detection of ovarian cancer. *Clinical Epigenetics, 12*(1), 1–10. https://doi.org/10.1186/s13148-020-00919-2

Torres, M. P., Prasad, R., & Srivastava, S. (2018). Liquid biopsy in ovarian cancer. *Cancer Letters, 413*, 243–249. https://doi.org/10.1016/j.canlet.2017.11.039

Vizza, E., Corrado, G., De Angeli, M., Carosi, M., Mancini, E., Baiocco, E., ... & Caserta, D. (2019). Exosomal miRNAs in urine as biomarkers for endometrial cancer. *International Journal of Molecular Sciences, 20*(3), 562. https://doi.org/10.3390/ijms20030562

Widschwendter, M., Jones, A., Evans, I., Reisel, D., & Ryan, A. (2021). Epigenome-based early detection of women's cancer from cervical fluids. *Nature Communications, 12*(1), 1–10. https://doi.org/10.1038/s41467-021-22062-0

Zavesky, L., Jandakova, E., Turyna, R., Langmeierova, L., Weinberger, V., Minar, L., ... & Duskova, M. (2017). Exosomal mRNA and miRNA markers in ovarian cancer. *International Journal of Molecular Sciences, 18*(5), 965. https://doi.org/10.3390/ijms18050965

Zhang, M., Cheng, S., Jin, Y., Zhao, Y., Wang, Y., & Wang, J. (2022). Circulating microRNAs as potential biomarkers for diagnosis and prognosis in endometrial cancer. *Frontiers in Oncology, 12*, 836108. https://doi.org/10.3389/fonc.2022.836108

Zhang, W., Yang, S., & Liu, Y. (2021). Diagnostic value of circulating biomarkers for ovarian cancer: A systematic review and meta-analysis. *Frontiers in Oncology, 11*, 701856. https://doi.org/10.3389/fonc.2021.701856

Zhou, J., Gong, G., Tan, H., Dai, F., Zhu, X., Chen, Y., & Wang, J. (2020). Plasma microRNA panel to diagnose ovarian cancer: A multicenter validation study. *Journal of Clinical Oncology, 38*(15), 1705–1714. https://doi.org/10.1200/JCO.19.02770

Zhou, Q., Li, W., Leng, B., Zheng, W., He, Z., & Zuo, M. (2019). Circulating cell-free DNA as a biomarker for ovarian cancer: A systematic review and meta-analysis. *PLOS One, 14*(4), e0215023. https://doi.org/10.1371/journal.pone.0215023

Zondervan, K. T., Becker, C. M., & Missmer, S. A. (2020). Endometriosis. *New England Journal of Medicine, 382*(13), 1244–1256. https://doi.org/10.1056/NEJMra1810764